MARKET

EPRX

EPRX

Eupraxia Pharmac
NASDAQ
6.34
-0.09
-1.40%
After Hours: 6.34 0 0.00% 16:10 07/14 EDT
OPEN
6.26
PREV CLOSE
6.43
HIGH
6.45
LOW
6.25
VOLUME
186.67K
TURNOVER
--
52 WEEK HIGH
9.32
52 WEEK LOW
4.880
MARKET CAP
414.17M
P/E (TTM)
-6.5727
1D
5D
1M
3M
1Y
5Y
1D
Eupraxia Pharmaceuticals Appoints New Technical Operations Heads; Co-Founder Malone Steps Down
NASDAQ · 16h ago
Eupraxia Pharmaceuticals Overhauls Leadership and Operations Ahead of Key EoE Trial Milestone
TipRanks · 1d ago
Eupraxia chief scientific and operating officer Amanda Malone steps down
TipRanks · 1d ago
Eupraxia names Jeff Millard EVP technical operations as Amanda Malone steps down COO
PUBT · 1d ago
EUPRAXIA PHARMACEUTICALS STRENGTHENS EXECUTIVE LEADERSHIP TEAM TO SUPPORT NEXT PHASE OF GROWTH
Reuters · 1d ago
Weekly Report: what happened at EPRX last week (0706-0710)?
Weekly Report · 1d ago
Stifel Nicolaus Keeps Their Buy Rating on Eupraxia Pharmaceuticals (EPRX)
TipRanks · 4d ago
Eupraxia Pharmaceuticals Adds Veteran Drug Developers to Board as Pipeline Advances
TipRanks · 07/07 20:48
More
About EPRX
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The Company’s EP-104GI is in a Phase Ib/IIa trial, the RESOLVE trial, for the treatment of eosinophilic esophagitis (EoE). EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. The Company also completed a Phase IIb clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. In addition, the Company is developing a pipeline of later and earlier-stage long-acting formulations. Its potential pipeline indications include candidates for other inflammatory joint indications and oncology.

Webull offers Eupraxia Pharmaceuticals Inc stock information, including NASDAQ: EPRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EPRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EPRX stock methods without spending real money on the virtual paper trading platform.